3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Breast
1
Conditions
Central Nervous System Neoplasms
12
Astrocytoma
10
Brain Neoplasms
9
Lymphoma, Non-Hodgkin
8
Gliosarcoma
8
Glioblastoma
8
Oligodendroglioma
7
Lymphoma, Large B-Cell, Diffuse
7
Lymphoma
7
Glioma
7
Lymphoma, Mantle-Cell
6
Lymphoma, Follicular
5
Burkitt Lymphoma
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma, Large-Cell, Immunoblastic
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Ependymoma
4
Recurrence
3
Lymphoma, T-Cell, Cutaneous
3
Lymphoma, B-Cell, Marginal Zone
3
Hodgkin Disease
3
Neuroectodermal Tumors, Primitive
2
Multiple Myeloma
2
Medulloblastoma
2
Lymphoma, B-Cell
2
Unspecified Adult Solid Tumor, Protocol Specific
1
Rectal Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Pinealoma
1
Pediatric Brain Tumor
1
Interventions
pembrolizumab
58
Gemcitabine
37
Biopsy
33
Specimen Handling
32
Paclitaxel
30
Magnetic Resonance Spectroscopy
30
Nivolumab
29
Cisplatin
25
Irinotecan
24
Carboplatin
24
Cyclophosphamide
23
Fluorouracil
22
Bevacizumab
22
Docetaxel
21
Oxaliplatin
19
Leucovorin
18
Ipilimumab
17
Cetuximab
17
Capecitabine
17
130-nm albumin-bound paclitaxel
16
Everolimus
15
Albumin-Bound Paclitaxel
15
Trastuzumab
13
olaparib
12
Pemetrexed
12
Erlotinib Hydrochloride
12
spartalizumab
11
Sorafenib
11
Radiosurgery
11
trastuzumab deruxtecan
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Neoplasm Metastasis
×
Carmustine
×
Clear all
NCT04150042
2026-01-29
SHARON
General Oncology, Inc.
Phase 1
Recruiting
24 enrolled